# JCAR PACKAGE WRITTEN COMMENTS/DHHS RESPONSE-ALS

NAME OF PERSON PROVDING COMMENTS	ORGANIZATION	RULE NUMBER	COMMENT	DHHS RESPONSE
Doris Allen; William Allen, M;, Sheri Mark-Slaim RN, JD, President; Hilary King; Christina Clark; Jon Gerych; James Hiller, J.D.; Clifford Lampe, Ph.D.; Paula Morning-Carter; Scott Pranger; Lisa Rosenberg; Brian Roth, D.O.; John Scarbrough. Comment sent by Mike Ritter, U of M.	University of Michigan-ALS Center of Excellence		The National Advisory Board of the ALS Center of Excellence at Michigan Medicine/University of Michigan is writing this letter in full support of the state of Michigan moving forward in making ALS a reportable disease through a formal registry, and with Rule Set 2022-13 HS. We believe that the data collected by this registry will assist ALS physicians and ALS researchers in Michigan in their mission to find identifiable risk factors for the disease, leading to possible effective treatments or prevention. Each member of this Board has had ALS touch their lives in a personal way, so we are very aware of the devastation of this disease and lack of effective treatments to date. Without data collected by the MDHHS, we will not know where clusters of disease may be occurring, what elements these cases have in common, and where	DHHS in support of the written comments.
Ximena Arcila-Londono, MD Director, Harry J. Hoenselaar ALS Clinic Henry Ford Health Neuroscience Brian Callaghan, MD, MS Director, Multidisciplinary ALS Clinic VA Ann Arbor Health System Michelle Crooks, MD Medical Director, Bronson Neuroscience Bronson Stephen Goutman, MD, MS Director, Pranger ALS Clinic University of Michigan Medicine Melanie Taylor, MD Director, Hauenstein Neurosciences ALS Clinic Trinity Health Paul Twydell, DO Director, ALS Clinic Neurosciences Integrated Care Campus-Beltline Corewell Health Medical Group Comment sent by Mike Ritter, U of M	ALS Directors at Various Medical Facilities		As directors of the major ALS Clinics in the State of Michigan, we are writing to convey our strongest support for making amyotrophic lateral sclerosis (ALS) a reportable disease in Michigan. ALS is a debilitating neurodegenerative disease that involves progressive loss of motor neurons that control voluntary muscle function. Its unrelenting and ultimately fatal nature requires evolving multidisciplinary support as the disease advances, but barriers to acquiring this multidisciplinary care have a significant impact on quality of life for all impacted by ALS.	DHHS is in support of the written comments.

To the Michigan Department of Health and Human Services,

As directors of the major ALS Clinics in the State of Michigan, we are writing to convey our strongest support for making amyotrophic lateral sclerosis (ALS) a reportable disease in Michigan. ALS is a debilitating neurodegenerative disease that involves progressive loss of motor neurons that control voluntary muscle function. Its unrelenting and ultimately fatal nature requires evolving multidisciplinary support as the disease advances, but barriers to acquiring this multidisciplinary care have a significant impact on quality of life for all impacted by ALS.

The data collected by the Michigan Department of Health and Human Services through an ALS registry will provide critical insight into the clinical care needs for individuals with ALS by helping us understand how currently available resources are being utilized and by identifying whether there are underserved areas where access to the required multidisciplinary care is lacking. This knowledge will inform improved care management and have considerable benefits for both those affected by ALS and their caregivers. Notably, the scientific advances made possible by having a comprehensive registry of individuals in our state can likewise enable much-needed diagnostic, prognostic, and therapeutic breakthroughs as well as inform potential prevention strategies.

Once again, we offer our utmost support for making ALS a reportable disease in Michigan. If there is anything else we can do to help facilitate this endeavor, please let us know.

Sincerely,

Ximena Arcila-Londono, MD Director, Harry J. Hoenselaar ALS Clinic Henry Ford Health Neuroscience

Brian Callaghan, MD, MS

Director, Multidisciplinary ALS Clinic

VA Ann Arbor Health System

Michelle Crooks, MD

Medical Director, Bronson Neuroscience

Bronson

Stephen Goutman, MD, MS Director, Pranger ALS Clinic University of Michigan Medicine

Melanie Taylor, MD

Director, Hauenstein Neurosciences ALS Clinic

Celon Tape MD

Trinity Health

Paul Twydell, DO

Director, ALS Clinic

Neurosciences Integrated Care Campus-Beltline

Corewell Health Medical Group



# ALS CENTER OF EXCELLENCE

**Board of Directors** 

Sheri Mark-Slaim, R.N., J.D. **President** 

Michael Ritter, M.D. Managing Director

Members:

Doris Allen

William Allen, M.D.

Christina Clark

Jon Gerych

James Hiller, J.D.

Hilary King

Clifford Lampe, Ph.D.

Paula Morning-Carter

Scott Pranger

Lisa Rosenberg

Brian Roth, D.O.

John Scarbrough

#### Office

Biomedical Science Research Bldg. 109 Zina Pitcher Place 5017 BSRB Ann Arbor, MI 48 I09 (734) 763-7274 phone (734) 763-7275 fax

To the Michigan Department of Health and Human Services,

The National Advisory Board of the ALS Center of Excellence at Michigan Medicine/University of Michigan is writing this letter in full support of the state of Michigan moving forward in making ALS a reportable disease through a formal registry, and with Rule Set 2022-13 HS. We believe that the data collected by this registry will assist ALS physicians and ALS researchers in Michigan in their mission to find identifiable risk factors for the disease, leading to possible effective treatments or prevention. Each member of this Board has had ALS touch their lives in a personal way, so we are very aware of the devastation of this disease and lack of effective treatments to date.

Without data collected by the MDHHS, we will not know where clusters of disease may be occurring, what elements these cases have in common, and where efforts should be centered at for monitoring or preventing ALS.

We are happy to provide support with further letter writing or emails if beneficial

Sincerely,

January 23, 2025

Sheri Mark-Slaim RN, JD, President

Shri March

Hilary King

John Scarbrough

Sin Mocarly

Lisa Rosenberg

Doris Allen

William Allen, MD

Jon Gerych

Paula Morning-Carter

Brian Roth, DO

8

Scott Pranger

Clifford Lampe, PhD

Scott L. Pranger

Christina Clark

Christina L. Clark

James Hiller, JD

Jam. Hiller

From: Anderson, Beth E. (DHHS)
To: Brennan, Mary (DHHS)

**Subject:** FW: Updated letters of support for ALS Rules Set 2022-13 HS

**Date:** Wednesday, February 12, 2025 9:06:25 AM

Attachments: UpdatedUM ALS BofD Letter to State of MI1 25final.pdf

<u>UpdatedClinicDirectorLettertoState1 25.pdf</u>

From: Ritter, Mike <denritte@med.umich.edu> Sent: Thursday, January 23, 2025 12:50 PM

To: Anderson, Beth E. (DHHS) <AndersonB@michigan.gov>; MDHHS-AdminRules <MDHHS-

AdminRules@michigan.gov>

Subject: Updated letters of support for ALS Rules Set 2022-13 HS

CAUTION: This is an External email. Please send suspicious emails to abuse@michigan.gov

## Good morning,

Attached are the two letters of support for the forum for public comment – for the Administrative Rules for ALS Reporting (Rule Set 2022-13 HS) – for February 12, 2025.

One is from the 6 ALS Clinic medical directors in the state of Michigan The other is from our entire Michigan Medicine National Advisory Board

Thank you for your consideration, Mike Ritter MD

### D. Michael Ritter MD

MANAGING DIRECTOR | ALS Center of Excellence at Michigan Medicine and the Neuronetwork for Emerging Therapies

Michigan Medicine | Department of Neurology

300 North Ingalls Street Room NI3D02 Ann Arbor, Michigan 48109

Phone: (734) 936-0996 | denritte@med.umich.edu

https://www.umich-als.org

https://medicine.umich.edu/dept/mneuronet

\*

Electronic Mail is not secure, may not be read every day, and should not be used for urgent or sensitive issues